Abstract:Importance: Cell therapy may be helpful for cardiac disease but has been fraught with poor cell retention and survival after transplantation. Objective: To determine whether cell-laden hydrogel treatment is safe and feasible for patients with chronic ischemic heart disease (CIHD). Design, setting, and participants: This randomized, double-blind clinical trial was conducted between March 1, 2016, and August 31, 2019, at a single hospital in Nanjing, China. Among 115 eligible patients with CIHD, 50 patients with left ventricular ejection fraction of 45% or less were selected to receive elective coronary artery bypass grafting (CABG) and additionally randomized to cell-plus-collagen treatment (collagen/cell group), cell treatment alone (cell group), or a control group. Sixty-five patients were excluded because of severe comorbidities or unwillingness to participate. Forty-four participants (88%) completed the study. The last patient completed 12 months of follow-up in August 2019. Analyses were prespecified and included all patients with available data. Interventions: During CABG, patients in the collagen/cell group were treated with human umbilical cord-derived mesenchymal stromal cell (hUC-MSC)-laden collagen hydrogel intramyocardial injection, and the cell group was treated with hUC-MSCs alone. Patients in the control group underwent CABG alone. Main outcomes and measures: The primary outcome was safety of the cell-laden collagen hydrogel assessed by the incidence of serious adverse events. The secondary end point was the efficacy of treatment, according to cardiovascular magnetic resonance imaging-based left ventricular ejection fraction and infarct size. Results: Fifty patients (mean [SD] age, 62.6 [8.3] years; 38 men [76%]) were enrolled, of whom 18 were randomized to the collagen/cell group, 17 to the cell group, and 15 to the control group. Patient characteristics did not differ among groups at baseline. For the primary end point, no significant differences in serious adverse events, myocardial damage markers, and renal or liver function were observed among all groups after treatment; the collagen/cell and cell groups each had 1 case of hospitalization because of heart failure, and no serious adverse events were seen in the control group. At 12 months after treatment, the mean infarct size percentage change was -3.1% (95% CI, -6.20% to -0.02%; P = .05) in the collagen/cell group, 5.19% (-1.85% to 12.22%, P = .35) in the cell group, and 8.59% (-3.06% to 20.25%, P = .21) in the control group. Conclusions and relevance: This study provides, to our knowledge, the first clinical evidence that the use of collagen hydrogel is safe and feasible for cell delivery. These findings provide a basis for larger clinical studies. Trial registration: ClinicalTrials.gov Identifier: NCT02635464.

Safety and Efficacy of Intracoronary Ad-HGF Administration for Treating Severe Coronary Disease: Results from Long-Term Follow-Up of a Phase I Clinical Trial

Safety and Efficacy of Adenovirus Carrying Hepatocyte Growth Factor Gene by Percutaneous Endocardial Injection for Treating Post-infarct Heart Failure: A Phase IIa Clinical Trial

Phase I Clinical Trial on Intracoronary Administration of Ad-hHGF Treating Severe Coronary Artery Disease

Hepatocyte growth factor plays a critical role in the regulation of cytokine production and induction of endothelial progenitor cell mobilization: a pilot gene therapy study in patients with coronary heart disease.

Safety and Efficacy of Intracoronary Hypoxia-Preconditioned Bone Marrow Mononuclear Cell Administration for Acute Myocardial Infarction Patients: the China-Ami Randomized Controlled Trial

Abstract 20556: Safety and Efficacy of Intracoronary Hypoxia-PrecondItioned Bone Marrow Mononuclear Cells Administration for Acute Myocardial Infarction Patients

[Effect of Intracoronary Adenovirus Vector Encoding Hepatocyte Growth Factor Gene on Hematopoietic Stem Cells Mobilization in Patients with Extensive Coronary Heart Disease].

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia

[A Prospective, Randomized, Controlled Trial of Autologous Mesenchymal Stem Cells Transplantation for Dilated Cardiomyopathy].

Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study.

Effect of Intramyocardial Grafting Collagen Scaffold With Mesenchymal Stromal Cells in Patients With Chronic Ischemic Heart Disease: A Randomized Clinical Trial

Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model

Effects of Adenovirus-Mediated Hepatocyte Growth Factor Gene Therapy on Postinfarct Heart Function: Comparison of Single and Repeated Injections

Improvement of Heart Function in Postinfarct Heart Failure Swine Models after Hepatocyte Growth Factor Gene Transfer: Comparison of Low-, Medium- and High-Dose Groups

Induction of Collateral Artery Growth and Improvement of Post-Infarct Heart Function by Hepatocyte Growth Factor Gene Transfer

Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial

[Intracoronary and Hypodermic Injection of Granulocyte Colony-Stimulating Factor Improved Cardiac Function in Swine with Chronic Myocardial Ischemia].

E0367 Effect of Treatment of Hepatocyte Growth-Promoting Factor on Improvement of Myocardial Ischaemia and Cardiopulmonary Functional Capacity During the Exercise in Patients with Severe Coronary Heart Disease

IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients With Angina and Nonobstructive Coronary Arteries

Intracoronary Administration of Autologous Adipose Tissue-Derived Stem Cells Improves Left Ventricular Function, Perfusion, and Remodelling after Acute Myocardial Infarction.

Recruitment of Stem Cells by Hepatocyte Growth Factor Via Intracoronary Gene Transfection in the Postinfarction Heart Failure